Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases.
Manuel Pombo-SuarezDaniel Seoane-MatoFederico Díaz-GonzálezFernando Sánchez-AlonsoMarta Sánchez-JareñoLuis Cea-CalvoIsabel CastrejonPublished in: Advances in rheumatology (London, England) (2023)
In patients who discontinued non-TNFi, most of whom received golimumab as third/subsequent line of therapy, one-third of patients remained on golimumab at year 4. Retention rates were higher in patients with axSpA and PsA than in those with RA.